SphingoTec develops innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions.
Sphingotec GmbH has raised $5.5M in total funding. The most recent round was Series C. The last funding was announced in August 2024.
Sphingotec GmbH's investors include Wellington Partners, NRW.BANK, Brandenburg Kapital, HBM Partners, HBM Healthcare Investments.
Sphingotec GmbH is headquartered in Hohen Neuendorf, Germany.
SphingoTec develops innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions.
Sphingotec GmbH is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sphingotec GmbH — Funding & Investors." VCBacked, August 8, 2024, https://www.vcbacked.co/company/sphingotec-gmbh. Accessed August 15, 2026.
VCBacked. (2024). Sphingotec GmbH — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/sphingotec-gmbh
{{cite web |title=Sphingotec GmbH — Funding & Investors |url=https://www.vcbacked.co/company/sphingotec-gmbh |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated